Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results.
Leuk Res, 2012/9;36(9):1134-40.
Franiak-Pietryga I[1], Maciejewski H, Wolowiec D, Salagacka A, Blonski JZ, Janus A, Kotkowska A, Wawrzyniak E, Ghia P, Mirowski M, Robak T, Korycka-Wolowiec A
Affiliations
PMID: 22608309DOI: 10.1016/j.leukres.2012.04.026
Impact factor: 3.715
Abstract
The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan Low Density Array for 96 gene transcripts was used. Those modifications followed two distinctive patterns largely overlapping the IGHV mutational status. In the IGHV-mutated group, the expression of many proapoptotic genes increased after treatment as compared to initial value. Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status.
MeSH terms
Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cladribine; Cluster Analysis; Cyclophosphamide; DNA Mutational Analysis; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genes, Immunoglobulin Heavy Chain; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Rituximab; V(D)J Recombination
More resources
EndNote: Download